Filtered By:
Source: The Annals of Pharmacotherapy
Condition: Bleeding
Drug: Clopidogrel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Vorapaxar in Atherosclerotic Disease Management.
CONCLUSION: Vorapaxar is approved for use with aspirin and/or clopidogrel in the secondary prevention of cardiovascular events in stable patients with peripheral arterial disease or a history of MI. However, the addition of vorapaxar to other antiplatelets can significantly increase the risk of bleeding. It is, therefore, essential to balance the need for further reduction of risk of thrombotic event with patient's individual bleeding risk.
PMID: 25680760 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 13, 2015 Category: Drugs & Pharmacology Authors: Cheng JW, Colucci V, Howard PA, Nappi JM, Spinler SA Tags: Ann Pharmacother Source Type: research
